医学
阿莫西林
内科学
幽门螺杆菌
不利影响
胃肠病学
随机对照试验
甲硝唑
抗生素
微生物学
生物
作者
Jie Hu,Hao Mei,Na‐Yun Su,Wen‐jing Sun,Dekui Zhang,Lilin Fan,Ping He,Jie Pan,Xing‐wei Wang,Pei‐Ying Zou,Yu‐Xiang Liu,Yan Guo,Chun‐Hui Lan
出处
期刊:Helicobacter
[Wiley]
日期:2023-05-09
卷期号:28 (4): e12970-e12970
被引量:69
摘要
BACKGROUND: Potassium-competitive acid blockers (P-CAB) are recommended for the treatment of Helicobacter pylori infections, but dual therapy of P-CAB with amoxicillin has been poorly studied. The current study compared the efficacy, adverse reactions, compliance, and effects on gut microbiota of 14-day vonoprazan-amoxicillin (VA) dual therapy with esomeprazole, bismuth potassium citrate, amoxicillin, and metronidazole (EBAM) quadruple therapy in treatment-naive patients with H. pylori. MATERIALS AND METHODS: C urea breath tests (UBT) 4-6 weeks post-treatment. Fecal samples were collected, and gut microbial populations were analyzed by 16S rDNA and metagenomic sequencing technology. RESULTS: Eradication rates of H. pylori in the VA and EBAM groups were 88.7% and 91.8%, respectively, according to intention-to-treat (ITT) analysis; 95.6% and 96.7% with per-protocol (PP) analysis; and 94.5% and 96.7% with modified ITT (mITT) analysis (all p > 0.05). The incidence of adverse reactions in the VA group was significantly lower compared to the EBAM group, and compliance within both groups was good. There was no difference in α-diversity or microbial composition in the VA and EBAM groups at one-month post-treatment compared to baseline, except for a markedly reduced abundance of Bacteroides in the EBAM group. CONCLUSION: VA therapy achieved excellent eradication rates with low adverse reactions, good compliance, and little impact on gut microbiota. VA therapy should be recommended as a first-line treatment against H. pylori.
科研通智能强力驱动
Strongly Powered by AbleSci AI